The new solution provides the block randomization methodology, to assign newly enrolled patients to a treatment group, in addition to the allocation methodology.
Balance offers sponsors built-in simulation to test the quality of the balance achieved across the sites, strata and factors, as well as the entire study.
With Balance’s new permuted block capability, the simulator can also be used to compare randomization results of dynamic allocation against block, the company said.
The new technology helps site staff access one integrated system to enroll subjects in treatment arms, receive treatment instructions and capture patient data.
Medidata president Glen de Vries said: "With the broader capabilities in Balance’s new version, sponsors and CROs can now choose either permuted block or dynamic allocation randomization, within our low-risk, easy-to-deploy and easy-to-use cloud-based randomization solution."